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This review of the literature consists of three sections.
First, papers concerning non-alcoholic fatty liver disease
(NAFLD) awareness among the general population, general prac-
titioners, and liver and non-liver specialists were retrieved and
analyzed to highlight the perception of disease, verify knowledge
of current recommendations, and identify the main difﬁculties
experienced in clinical practice.
Next, position papers and clinical practice guidelines issued by
International and National Hepatological Scientiﬁc Societies were
identiﬁed and critically assessed in order to pinpoint the areas of
convergence/difference.
Finally, practical suggestions on NAFLD diagnosis and manage-
ment in daily practice are provided and the open questions
highlighted.
 2013 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Non-alcoholic fatty liver disease (NAFLD), the hepatic counter-
part of the metabolic syndrome (MS) [1,2], encompasses a disease
spectrum spanning steatosis through non-alcoholic steatohepati-
tis (NASH) with/without cirrhosis, and hepatocellular carcinoma
(HCC) [3]. The obesity and type 2 diabetes (T2D) pandemic and
the improved management of chronic viral hepatitis have
resulted in NAFLD becoming a leading cause of chronic liver dis-Journal of Hepatology 20
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cardiovascular disease.ease (CLD) [4] and a major health concern owing to hepatic and
extrahepatic morbidity/mortality [5–7].
Such a shift in the epidemiology of CLD has left practicing cli-
nicians somewhat puzzled in identifying and treating this NAFLD
‘‘epidemic’’ [8–12]. Moreover, an ever increasing number of prac-
tice guidelines on NAFLD diagnosis and management issued by
eminent Scientiﬁc Societies may probably add to the uncertain-
ties concerning the best conduct to follow in clinical practice.
Our paper aims at (1) highlighting the perception of NAFLD
among practicing physicians, (2) providing a critical, comparative
analysis of the statements on NAFLD diagnosis and management,
issued by clinical practice guidelines and technical reviews of Sci-
entiﬁc Societies, (3) offering practical suggestions on the contro-
versial topics and deﬁning the unsettled questions.Methods
We conducted a PubMed database search (keywords: general
practice and/or primary care and/or specialists and/or physi-
cians and/or awareness and/or perception and/or liver steatosis
and/or fatty liver and/or NAFLD and/or NASH and/or guidelines
and/or recommendations. Limits: December 2012 and English
language) aimed at ascertaining: (a) the awareness/perception
of the importance of NAFLD-NASH among potential patients
and practicing physicians [both general practitioners (GPs)
and specialists] and (b) guidelines/consensus/recommendations
for NAFLD diagnosis and management issued by Medical
Societies.
Six studies meeting the inclusion and exclusion criteria inves-
tigated current beliefs and practices of NAFLD among the general
population, GPs and liver and non-liver specialists [8–13]. More-
over, three further studies [14–16] addressing the clinical
approach of practicing physicians towards pediatric NAFLD were
identiﬁed (Table 1).
Five position papers and clinical practice guidelines, issued by
the European Association for the Study of the Liver (EASL) [17],
Asian-Paciﬁc Working Party for NAFLD (APWP-NAFLD) [18], Chi-
nese Liver Disease Association (CLDA) [19], Italian Association for
the Study of the Liver (IASL) [20] and American Gastroenterolog-
ical Association (AGA)-American Association for the Study of
Liver Disease (AASLD)-American College of Gastroenterology
(ACG) [21], were identiﬁed. Three out of ﬁve such reports are
evidence-based [19–21]. A single position paper on diagnosis of13 vol. 59 j 859–871
Table 1. Analysis of reports from real-life clinical practice.
Author, yr [Ref.] Methods Main findings
Leung CM, et al.,
2009 
[13]
Telephone survey on NAFLD knowledge among 
521 subjects randomly selected from the general 
population in Hong Kong.
Among those interviewed, 83% had never come across the term “NAFLD.” Among those who had heard of NAFLD, 
Before/after teaching workshop - Questionnaire (%): 4.7/42.7 indicated NAFLD as the first cause of undefined
diabetic patients with persistent hypertransaminaseima, 78/91 indicated diet as the first approach. 34.1% should avoid
42% had no idea about prevalence, 47% knew nothing about clinical presentation, 78% thought that blood tests could 
provide definite diagnosis, about 50% mistook associated risk factors and 81% perceived their knowledge of NAFLD as
inadequate. 
Grattagliano I, et al.,
2008 
[8]
Online questionnaire and clinical survey about 
NAFLD knowledge and management before and 
after attending a teaching workshop among 56 
GPs in Italy. 
persistent hypertransaminasemia, 70/<10 underestimated NAFLD prevalence in general population, 36.6/76.2 would 
screen diabetic subjects, 39.5/100 should make diagnosis after exclusion of all other causes of liver steatosis, 23.2/61.9 
should manage NAFLD patients with diet and a new check after 6 months, 2.3/80.9 should ask for LB in over 50 
statins.
Practice check: improvement in screening of risk patients, searching for NASH and managing NAFLD.
Drinking habits registered in only 20.4% of CLD patients. 81.9% of patients with undefined CLD were overweight/
Compared to specialists, GPs significantly less likely to be aware of official guidelines, to rate NAFLD as a common 
Loguercio C, et al., 
2011 
[10]
5-yr retrospective analysis from 104 GPs and 
6550 patients with CLD in Italy. obese. In patients with liver steatosis (NAFLD + AFLD): alcohol consumption recorded in 30.2%, BMI recorded in 
59.5%, US performed in 37.9% of patients. No record of additional tests including insulin, HOMA index, ferritin, GGT, 
lipids and HBV- HCV markers.
Kallman JB, et al., 
2009 
[9]
Survey questionnaire about screening for HBV, 
HCV and NAFLD among 103 GPs, 59 gastroen-
terologists and 52 hepatologists in USA.
cause of liver disease, to screen for NAFLD in asymptomatic patients with diabetes but believed more strongly that 
available treatments for NAFLD are effective. Hepatologists endorsed appropriate screening scenarios more frequently 
than gastroenterologists and GPs.
Bergqvist CJ, et al., 
2012 
[11]
Face-to-face questionnaire assessing beliefs and 
practices regarding NAFLD among 100 non-liver 
specialists in Australia.
75% underestimated the prevalence of NAFLD in the general population and 89% in high-risk patients. 57% considered 
alcohol consumption to be strongly associated with NAFLD. 60% deemed simple steatosis to confer excess liver-
related mortality. 66% thought that NASH can be diagnosed with liver imaging. 71% made no referrals to hepatology 
services for suspected NAFLD.
Ratziu V, et al., 
2012 
[12]
Survey assessing the clinical burden, perceived 
severity, and management patterns of 
NAFLD among 352, board-certified, hepato-
gastroenterologists in France.
Most NAFLD patients were referred by GPs and only 20% by specialists. Conversely, 87% of hepatologists referred 
NAFLD patients for specialistic evaluation of potential co-morbidities. 65% would diagnose NASH irrespective of 
the concurrent CLD due to other etiology if MRFs were present. No agreement on the threshold of daily alcohol 
consumption that rules out NASH.
Most physicians would overrate the importance of raised transaminases for the diagnosis of NASH. 62% delay LB after 
diet and lifestyle changes. 90% used non-invasive fibrosis markers. Roughy half did not measure fasting insulin/HOMA,
22% did not measure waist circumference. 73% monitored NAFLD patients themselves; most with yearly US and only 
16% with fasting insulin/HOMA.
72% of patients were treated with non-pharmacological measures, often following referral to the endocrinologist/
nutritionist. 42% recommended total abstinence from alcohol. Drugs treatment (metformin, UDCA, venesection, 
glitazones and vitamin E) was prescribed in only 28% of NAFLD patients.
Fishbein M, et al., 
2005 
[15]
requests for diagnostic testing of 18 physicians 
Analysis of physical examination findings and
involved in pediatric primary care on 11 obese 
children (4 with NAFLD) in USA.
(10%), and LTs (8.6%).
Most commonly performed laboratory tests: fasting blood glucose (23%), lipid profile (20%), thyroid function tests
Hepatomegaly was identified in 0.5% of obese children.
Most common consultations: dietary (46%) and endocrinology (16%).
Exercise program recommended in 4%.
Abdominal imaging was requested in none of the encounters.
In obese children with NAFLD, clinicians detected hepatomegaly in only 1.4% and requested LTs in 12.5% of encoun-
ters.
Sivertsen LM, et al., 
2008 
[14]
Questionnaire assessing attitudes on diagnosis 
and management of overweight/obese children 
and awareness of clinical practice guidelines 
among 137 GPs in Australia.
The guidelines on the management of childhood obesity in general practice were reported to be used by 30% of 
respondents.
9% of GPs used BMI charts to correctly diagnose childhood obesity. 30% assessed for fatty liver in overweight/obese 
children.
Over 80% of prescribed interventions were consistent with guidelines.
Riley MR, et al., 
2005 
[16]
Retrospective chart review of 2256 pediatric 
outpatient visits at 2 academic hospitals (general 
pediatricians, pediatric endocrinologists and 
gastroenterologists) in USA.
Children with BMI 85 to 89%, 90 to 94% and ≥95% were given a diagnosis of overweight during 4, 8 and 48% of visits, 
respectively.
General pediatrics, pediatric endocrinology and gastroenterology visits of overweight children included NAFLD screen-
ing in 2, 10 and 23% and metabolic screening in 8, 34 and 3% of cases, respectively.
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NAFLD in pediatrics was found (European Society for Pediatric
Gastroenterology, Hepatology, and Nutrition [ESPGHAN]) [22].
The ‘‘real world’’ reports were analyzed to highlight the actual
perception of NAFLD, verify the awareness of current recommen-
dations, and identify the main difﬁculties experienced in clinical
practice [8–16].
The recommendations issued by Scientiﬁc Societies were crit-
ically assessed in order to pinpoint the areas of convergence/
difference.
The single position paper for pediatric medicine [22] was also
examined in order to provide information useful to those
involved in pediatric care.
Finally, prompted by the analysis of the reports of practicing
physicians [8–16] and the systematic analysis/comparison of
guidelines [17–22], we provide practical suggestions on NAFLD
diagnosis and management in daily practice and highlight the
open questions and future research.Results and comments
Analysis of reports concerning issues from ‘‘real-life’’ practice and
selected guidelines disclosed the following major topics regard-
ing NAFLD diagnosis and management that remain a matter of
dispute (Tables 1 and 2):
(1) Deﬁnition and initial assessment of suspected NAFLD
patients;
(2) Screening strategies for NAFLD;
(3) Diagnostic strategies: non-invasive assessment and liver
biopsy (LB);
(4) Management of NAFLD patients;
(5) Follow-up strategies of NAFLD patients;
(6) Pediatric NAFLD.What is the deﬁnition of NAFLD and which is the initial
assessment of suspected NAFLD patients?
Analysis of reports from real-life clinical practice
The single study evaluating the awareness of NAFLD in the gen-
eral population demonstrated that the vast majority of people
(83%) had never come across the term NAFLD; knowledge about
NAFLD diagnosis and risk factors was also inadequate among
those who had ever heard of it [13].
Similarly, several studies showed that knowledge about
NAFLD diagnosis and assessment is relatively poor among GPs.
An American study showed that GPs were less likely to consider
NAFLD as a common cause of liver disease than Hepato-Gast-
roenterologists [9]. These ﬁndings are consistent with an Italian
survey: only 4.7% of GPs indicated a metabolic cause as the ﬁrst
determinant of an ‘‘undeﬁned’’ persistent hypertransaminasemia.
Moreover, a great variability in diagnostic approach to NAFLD
was described [8]. In Loguercio’s retrospective analysis involving
104 GPs, alcohol consumption, BMI, transaminases, and ultraso-
nography (US) were assessed only in a minority of patients with
liver steatosis; no additional tests [markers of insulin resistance
(IR), lipid proﬁle, viral hepatitis serologies] were recorded [10].
In a recent survey of 100 hospital non-liver specialists, >90%
appreciated that traditional cardiovascular risk factors predicted
NAFLD and acknowledged these to be common in non-liverJournal of Hepatology 201patients. Moreover, 57% considered alcohol consumption to be
strongly associated with NAFLD [11].
A French survey among 352 Hepato-Gastroenterologists
showed that two-thirds would diagnose NAFLD irrespective of
the co-existence of other CLD, as long as metabolic risk factors
(MRFs) were present. There was no agreement on the threshold
of daily alcohol consumption that ruled out the diagnosis of
NAFLD. In the initial assessment of NAFLD patients, a large major-
ity of surveyed specialists collected information on BMI, blood
pressure, and glucose or lipid parameters; nonetheless, a sizeable
proportion never assessed surrogate markers of IR or measure-
ments of regional adiposity [12].
Analysis of guidelines
All guidelines agree that diagnosis of NAFLD relies on both imag-
ing or histological evidence of hepatic steatosis and exclusion of
causes of secondary hepatic fat accumulation; there is full agree-
ment that NAFLD is strictly associated with MRFs. All Scientiﬁc
Societies state that, because of the high prevalence of MRFs,
NAFLD can co-exist with other CLDs. There is universal consensus
that the metabolic proﬁle should be assessed, competing etiolo-
gies of steatosis and co-existing CLD should be ruled out, and
alcohol consumption should be estimated [17–21].
Regarding metabolic assessment, the majority of guidelines
[17–20] highlight the importance of testing insulin sensitivity.
However, there seems to be no consensus on how this should be
done. All societies agree that presence of overweight/obesity
should be evaluated through anthropometric measures (BMI,
waist circumference) and that blood pressure and serum lipids
measurement shouldbeperformedas aminimal initial assessment
[17–21]. Regarding the criteria to adopt for the diagnosis ofMS, the
American guideline [21] recommends the Adult Treatment Panel
III deﬁnition [23,24], whereas Asian-Paciﬁc Societies [18,19] rec-
ommend the International Diabetes Federation criteria [25].
All guidelines concur that all NAFLD patients should undergo
a careful familial and medical history, viral hepatitis and autoim-
mune serology, alpha1-antitrypsin, iron and copper status mea-
surement. The common association between chronic HCV
infection and hepatic steatosis and its implications for ﬁbrosis
progression and/or treatment response rate are mentioned by
all guidelines [17–21].
The threshold for hepatotoxic alcohol consumption to rule out
alcoholic liver disease varies as a function of local drinking cul-
ture/habits. European Associations [17,20] maintain a threshold
of 30 and 20 g of alcohol daily for men and women, respectively.
Similarly, the American guideline [21] suggests 210/140 g (=21/
14 drinks) of alcohol weekly, whereas Asian-Paciﬁc countries
[18,19] restrict to 140/70 g of alcohol weekly for men and
women, respectively. Moreover, the American guideline speciﬁ-
cally recommends a 2-year alcohol withdrawal for NASH clinical
trials candidate eligibility purposes [21]. This point is not dis-
cussed in other guidelines.
Comments
In recent years, the diagnostic strategy for NAFLD has evolved
from a diagnosis of exclusion towards a chieﬂy positive approach
based on the recognition of the underlying dysmetabolic milieu
[1,2]. In patients with suspected NAFLD, exclusion of competing
etiologies for steatosis is essential. To this end, endocrine disor-
ders [26], familial hypobetalipoproteinemia [27], alcohol abuse,3 vol. 59 j 859–871 861
Table 2. Analysis of guidelines.
AGA, AASLD, ACG 
[21]
CLDA 
[19]
IASL 
[20]
EASL 
[17]
APWP 
[18]
ESPGHAN 
[22]
Screening - +
(US and LTs 
in patients with 
MS)
/ +
(US and LTs in 
patients with MS 
and IR)
+
(US and LTs 
in patients with 
MS)
+
(US and LTs in 
overweight/obese 
children older than 3)
Initial evaluation
Metabolic 
assessment
+ + + + + +
Competing causes of 
steatosis
+ + + + + +
Alcohol consumption +
(M/F 21/14 drinks 
per wk)
+
(M/F 140/70 g 
weekly)
+
(M/F 30/20 g 
daily)
+
(M/F 30/20 g 
daily)
+
(M/F 140/70 g 
weekly)
/
Coexisting liver 
disease 
+ + + + + +
Non-invasive 
assessment
+
(NAFLD Fibrosis 
Score)
-
(only for 
research study)
+
(NAFLD 
Fibrosis 
Score and 
FibroScan®)
+
(serum markers 
and FibroScan®)
-
(only for 
research study)
-
(only for research 
study)
Liver biopsy +
(restricted to 
selected patients)
+
(restricted 
to selected 
patients)
+
(restricted 
to selected 
patients)
+
(restricted 
to selected 
patients)
+
(restricted 
to selected 
patients)
+
(restricted to 
selected patients)
Management /
Lifestyle intervention + + + + +
Pharmacological 
treatment
+
(pioglitazone and 
vitamin E in non-
diabetic biopsy-
proven NASH)
+ -
(reserved to 
controlled 
studies)
+
(glitazones, 
vitamin E and 
high-dose 
UDCA in NASH)
-
(reserved to 
controlled 
studies)
Bariatric surgery -
(but is not 
contraindicated 
in eligible obese 
NAFLD)
+
(in obese 
patients 
refractory 
to medical 
measures)
-
(reserved to 
controlled 
studies)
+
(in morbidly 
obese advanced 
fibrotic NASH) 
+
(in obese 
patients 
refractory 
to medical 
measures)
Metabolic control + + + + +
Follow-up /
Hepatologic + + + + +
Cardiovascular + + + + +
Oncologic - + +
(on individual 
basis)
- +
Children Pediatric NAFLD 
section
/ / / / Diagnostic aspects 
of pediatric NAFLD
+, recommended; -, not recommended; /, not mentioned.
Reviewand, particularly, HCV infection, given that HCV infection, diabe-
tes and steatosis are closely linked to one another [28–30], need
to be ruled out. Moreover, it is also necessary to carefully assess
for MRFs and the cardiovascular risk proﬁle. Furthermore, NAFLD
can occur together with other CLD, which may accelerate the pro-
gression of liver injury [31–35]. Accordingly, in liver patients
with MRFs, the presence of concurrent NAFLD should be evalu-
ated. Conversely, when steatosis is detected in patients with
CLD due to non-NAFLD etiology, a metabolic assessment is
needed. It is critical to deﬁne the appropriate standard anthropo-862 Journal of Hepatology 201metric, biochemical and imaging protocol to be followed to
detect NAFLD in clinical practice.
NAFLD deﬁnitely needs to be differentiated from alcoholic
fatty liver disease (AFLD). However, due to the low reliability of
the diagnostic methods (patient interview and biomarkers), a
clear distinction between the two conditions is difﬁcult [36–
39]. Moreover, the recommended thresholds of ‘‘signiﬁcant alco-
hol consumption’’ and the duration of alcohol withdrawal in
those with suspected NAFLD are arbitrary. In addition, an overlap
between alcohol consumption and metabolic disorders exists,3 vol. 59 j 859–871
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making a clear attribution of steatosis to AFLD as opposed to
NAFLD virtually impossible in the individual patient. For these
reasons, some authors consider this distinction of fatty liver dis-
ease artiﬁcial and poorly useful [40].
Key Points 1
• Awareness of NAFLD, its diagnosis, and risk factors
in the general population is poor. Knowledge about
NAFLD diagnosis and assessment is relatively 
inadequate among general practitioners, particularly
so in NAFLD pediatric patients. Specialists other than
hepatologists under-appreciate the overlap between
NAFLD and metabolic risk factors, thus missing a 
significant proportion of high-risk NAFLD patients.
Hepatologists themselves risk under-diagnosing NAFLD
due to over-reliance on transaminasesWho and how to screen for NAFLD?
Analysis of reports from real-life clinical practice
Grattagliano’s survey showed that 70% of Italian GPs underesti-
mated the prevalence of NAFLD among the general adult popula-
tion, only 36.6% would screen for NAFLD diabetic subjects and a
substantial subset of hypertransaminasemic patients were not
considered for NAFLD even in the presence of MRFs. Speciﬁc
training signiﬁcantly improved GPs’ ability in screening at-risk
patients [8]. The underestimation of the NAFLD problem by GPs
was conﬁrmed by another Italian study, in which an extremely
low prevalence of fatty liver was reported, and a high proportion
of patients were considered as affected by ‘‘undeﬁned’’ CLD
despite a high rate of overweight/obesity and an incomplete diag-
nostic work-up [10]. GPs are reported to be less familiar with cur-
rent recommendations and to use appropriate screening
strategies less frequently than hepato-gastroenterologists unless
they are fully aware of guidelines [9].
An Australian survey showed that also non-liver Specialists
underestimated the prevalence of NAFLD both in the general pop-
ulation and in high-risk patients, thus reﬂecting a low grade of
referrals to Hepatology services [11]. Accordingly, a French study
reported that only 20% of NAFLD patients seen in gastroenterol-
ogy practice were referred by specialists in the metabolic ﬁeld.
This survey stressed that among liver specialists there was an
over-reliance on transaminases instead of MRFs or US steatosis,
when considering the diagnosis of NAFLD [12].
Analysis of guidelines
The majority of guidelines [17–19] explicitly suggest the
opportunity to implement a screening policy in individuals at
high risk of NAFLD identiﬁed by the presence of MRFs and/or
IR. Two guidelines either fail to mention [20] or discourage
any screening policies [21]. Indeed, the most recent American
guideline [21] states that systematic screening for NAFLD is
not recommended not only in the general population but also
in high-risk patients, in family members and in obese children,
due to paucity of evidence.
All Scientiﬁc Societies who support screening suggest that it
should be done through both US and Liver Tests (LTs).Journal of Hepatology 201Comments
The prevalence of NAFLD in the general population ranges
from 6.3% to 51% depending on the method used to assess liver
steatosis and the population/ethnicity studied [41–45]. This prev-
alence can be signiﬁcantly higher in individuals with MRFs [46–
48]. Moreover, familial aggregation and heritability of NAFLD
have been consistently reported [49–52].
There are important differences concerning the deﬁnitions of
overweight/obesity and MS between Western and Asia-Paciﬁc
patients. In the Asian population, morbidity and mortality occur
at lower BMIs and smaller waist circumferences than in Cauca-
sians, justifying speciﬁc criteria for overweight/obesity and MS
representative of people living in the Asia-Paciﬁc region [25,53–
55].
Although the majority of NAFLD cases are strongly associ-
ated with overweight/obesity and T2D, different studies
reported a prevalence of NAFLD in the normal-weight popula-
tion between 7% and 16% [42,56–59]. These studies invariably
demonstrated that NAFLD is closely associated with metabolic
disorders, particularly IR, even in lean patients. NAFLD should
be considered an early predictor of metabolic derangements,
thus suggesting that IR, rather than frank diabetes or obesity,
is the alteration to be detected when screening for NAFLD.
Therefore, methods and thresholds to deﬁne subtle IR are
strongly needed in order to detect those patients at increased
risk of hepatic complications.
Compared to the general population, NAFLD is independently
associated with a signiﬁcantly higher all-cause mortality [5–
7,60–65], and cancer incidence [66,67], principally HCC [68,69],
increased incident T2D risk [6,70,71], greater prevalence/inci-
dence of cardiovascular disease (CVD) [72–75], and a higher rate
of major complications and death after surgery [76–78].
Based on the above reasons, detection of NAFLD should be
considered as a major task in the management of patients with
features of IR. Nevertheless, due to uncertainties surrounding
the best diagnostic and management strategy, unequivocal indi-
cations in NAFLD screening policies are lacking.
US, being safe, inexpensive, widely available, and having a
good performance when steatosis is present in at least 20–
30% of hepatocytes is an acceptable ﬁrst-line screening proce-
dure for NAFLD in clinical practice. However, the relatively
low acuity for mild steatosis, the low accuracy in morbid obes-
ity, and its operator-dependency are the main limitations
[79,80]. Interestingly, although not so sensitive as magnetic
resonance spectroscopy [81,82], US can nevertheless have a
lower threshold for fat detection than previously appreciated
[80]. Criteria used to deﬁne US steatosis need to be standard-
ized and semi-quantitated. Once such semi-quantitation is per-
formed through simple scores, US is able to predict metabolic
derangements and liver histology changes [83,84].
Despite the almost universal reliance on transaminases in
real-life practice, LTs are not considered a useful tool in NAFLD
screening. Indeed, the majority of NAFLD patients have normal
transaminases [42], which do not rule out histologically
advanced disease [85,86]. The deﬁnition of the ‘‘normal’’ trans-
aminases range is controversial. Transaminases reference
ranges currently used underestimate the prevalence of patients
with liver diseases and the upper limit of ‘‘normal’’ alanine
aminotransferase has been downgraded to 30 U/L for men
and 19 U/L for women [87–92].3 vol. 59 j 859–871 863
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• All guidelines agree that the diagnosis of NAFLD relies
on both imaging and histological evidence of hepatic
steatosis after exclusion of competing etiologies of
liver fat deposition (typically HCV infection, alcohol
consumption and other) in individuals with metabolic
risk factors. NAFLD patients should undergo a 
careful familial and medical history, viral hepatitis 
and autoimmune serology, alpha 1-antitrypsin, iron
and copper status measurement. The threshold for
hepatotoxic alcohol consumption and the extent of
alcohol withdrawal to rule out alcoholic liver disease
remain to be defined. NAFLD may well co-exist with
other chronic liver diseases, typically HCV infection.
The majority of guidelines suggest the opportunity to
implement a screening policy (through both US and
LTs) in individuals at high risk of NAFLD identified
by the presence of metabolic risk factors and/or IR.
LB should not be performed in all NAFLD patients
but should be restricted to those NAFLD patients 
presenting an increased risk for NASH or advanced
fibrosisHow to non-invasively assess inﬂammation and ﬁbrosis and
when to obtain an LB?
Analysis of reports from real-life clinical practice
Grattagliano reported that the majority of GPs indicated hyper-
transaminasemia or none as the best reason to ask for LB in NAFLD
subjects. Only 2.3% of GPs chose over 50 year-old diabetic patients
as potential candidates for LB. However, after attending a tailored
workshop, 80.9% indicated the latter as good candidates for LB and
a substantial proportion reconsidered a fraction of their previously
diagnosed NAFLD patients at potential risk of NASH [8].
The Australian survey among non-liver Specialists reported
that 98% correctly identiﬁed that NASH can be diagnosed on LB,
about three-quarters agreed that LTs are not sufﬁciently sensitive
to detect NASH, but 66% deemed that a diagnosis of NASH can be
based on imaging [11].
Ratziu showed that about two-thirds of Hepato-Gastroente-
rologists considered important the identiﬁcation of steatohepati-
tis or the staging of ﬁbrosis. However, the main indication for LB
was to gauge the ﬁbrosis stage. In fact, given the invasive nature
of LB, 38% would not perform this procedure to estimate hepatic
inﬂammation. Conﬁrming that transaminases levels impact on
the decision to perform an LB, 43% of hypertransaminasemic vs.
6% of normotransaminasemic NAFLD patients would be asked
to undergo an LB. Non-invasive ﬁbrosis markers were used by
90% of the surveyed physicians in clinical practice: the majority
used both serum markers and elastometry [12].
Analysis of guidelines
Initial non-invasive assessment of inﬂammation and ﬁbrosis is
suggested in clinical practice by some [17,20,21] but not all guide-
lines. CLDA and APWP restrict non-invasive assessment of NASH
and ﬁbrosis to research purposes alone [18,19]. European and Ital-
ian guidelines suggest the combined use of clinical and laboratory
parameters, serum markers, composite scores (particularly the864 Journal of Hepatology 201NAFLD ﬁbrosis score) and imaging methods (transient elastogra-
phy – FibroScan) in order to reduce the number of NAFLD patients
requiring LB [17,20]. The American guideline conﬁrms the clinical
utility of NAFLD ﬁbrosis score in identifying NAFLD patients with
higher likelihood of having advanced ﬁbrosis and highlights the
importance of MS as strong predictor of NASH [21].
There is universal agreement that LB should not be performed
in all patients. All guidelines recommend LB in NAFLD patients
presenting an increased risk for NASH or advanced ﬁbrosis [17–
21]. LB is considered in suspected NAFLD patients in whom there
is diagnostic uncertainty due to difﬁculties in excluding compet-
ing etiologies for hepatic steatosis and co-existing CLD by the
majority of guidelines [18,19,21]. The European guideline recom-
mends performing LB to assess concurrent NAFLD in patients
with other CLD, MRFs, and US steatosis [17]. Asian-Paciﬁc and
European guidelines suggest the opportunity to perform LB in
NAFLD patients subjected to surgical procedures for other pur-
poses [17,18]. All guidelines (implicitly or explicitly) recommend
LB in NALFD patients enrolled in clinical trials [17–21].
Comments
Simple steatosis is associatedwith a normal life expectancy and its
progression is limited to anecdotal case reports [93–95]. Con-
versely, NASH worsens in up to 30% of cases, evolving in cirrhosis
in a substantial fraction of cases [3,61,96]. Moreover, 30–75% of
cases of cryptogenic cirrhosis can be attributed to previously
unrecognized NASH [68,97–101]. Given that the presence of
inﬂammation at the initial LB is the strongest predictor of NAFLD
progression and that the degree of ﬁbrosis is the most important
prognostic factor, efforts of practicing physicians should be ori-
ented towards identiﬁcation of those patients with steatohepatitis
and/or advanced ﬁbrosis.
LB is the gold-standard for direct diagnosis of NASH and eval-
uation of inﬂammation/ﬁbrosis, however, its use is limited by
invasiveness, cost and sampling error [102]. Several non-invasive
methods for identifying patients with NASH or ﬁbrosis have been
proposed [5,103–106], but validated decisional algorithms ade-
quate for clinical practice are still lacking.
Key Points 3
• All NAFLD patients should undergo interventions 
aimed at promoting healthier lifestyles and strict control
of metabolic risk factors associated with NAFLD. 
Pharmacotherapy (glitazones, vitamin E, possibly
associated with high-dose UDCA) should be reserved
for NASH patients possibly in randomized controlled
trials. Concurrent metabolic risk factors associated
with NAFLD should be managed as clinically required
and drugs given as needed. Bariatric surgery, if 
otherwise indicated, is considered a valid option for
obese patients with NAFLD/NASH. Heavy alcohol
consumption should be discouraged. Light-moderate
alcohol consumption may exert favorable metabolic
effects and, perhaps, on liver outcomes. However,
in the absence of randomized controlled trials, all 
guidelines advise against prescribing low-moderate
alcohol consumption as a preventive/therapeutic 
strategy fort NAFLD. Hepatological and cardiovascular
follow-up is indicated in NAFLD patients. Oncologic
screening/surveillance should be considered on 
individual risk3 vol. 59 j 859–871
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How to treat NAFLD patients?Analysis of reports from real-life clinical practice
In the Italian survey, 78% and 91% of GPs, before and after the
workshop, respectively, indicated diet as the ﬁrst and best
approach to NAFLD. 34.1% stated that statins should be avoided
in NAFLD patients [8].
In Bergqvist’s study, 95% of non-hepatologists agreed that
management of NAFLD involves weight loss, physical exercise,
and treatment of concurrent MRFs. Further to lifestyle changes,
drugs to lose weight and bariatric surgery were included in
NAFLD management, whereas 75% of respondents excluded spe-
ciﬁc liver-directed drug therapy [11].
The French survey among hepatologists showed that 72% of
patients were treated with lifestyle changes only, while 28% were
treated with drugs further to non-pharmacological interventions.
The most frequently prescribed regimens were: metformin,
ursodesoxycholic acid, phlebotomy, glitazones, and vitamin E.
42% recommended total abstinence from alcohol; about 50%
allowed daily alcohol consumption of 10–30 g in male and 10–
20 g in female patients [12].Analysis of guidelines (Table 3)
There is universal consensus that all patients should undergo
interventions aimed at promoting healthier lifestyles and strict
control of MRFs associated with NAFLD. All guidelines agree that
lifestyle changes including weight loss, dietary changes, and
physical exercise should always be implemented as ﬁrst-line
option in all NAFLD patients [17–21].
With regard to the entity of weight loss, the Italian guideline
simply states that 0.5 kg/week weight loss should be considered
in overweight individuals [20], whereas the Chinese guideline
recommends more than 5% weight reduction in 6–12 months
[19]. The European guideline suggests that a weight loss of 7%
should be reasonable in overweight and mildly obese patients
[17]. Finally, American societies provide more speciﬁc indica-
tions: loss of at least 3–5% of body weight to improve steatosis,
and up to 10% to improve necroinﬂammation [21].
All societies concur in recommending a hypocaloric diet to
promote weight-loss [17–21]. However, while the Chinese guide-
line provides quantitative details (intake of 500–1000 kcal daily
for obese adults) [19], almost all guidelines identify qualitative
directions (low carbohydrate and saturated fat intake, avoidance
of fructose-enriched soft drinks and increased consumption of
ﬁbers and antioxidants-rich fruits and vegetables) [17,19,20].
All guidelines agree that heavy alcohol consumption should
be avoided in NAFLD patients. However, no guidelines encourage
mild-moderate intake [17–21].
All guidelines strongly recommend avoidance of sedentari-
ness and implementation of physical activity. The European
guideline is more accurate in suggesting at least 150 min per
week of moderate-intensity physical activity and at least
75 min per week of vigorous-intensity physical activity, further
to muscle strengthening twice a week [17]. Similarly, the Chinese
guideline recommends moderate aerobic exercise at least 4 times
weekly, with a minimum cumulated exercise time of 150 min
[19]. Moreover, European societies [17,20] and the Chinese
guideline [19] highlight behavior therapy as important in accom-
plishing weight loss.Journal of Hepatology 201Pharmacologic therapy should be reserved only to NASH. The
more conservative suggestion is to limit the use of drugs to ran-
domized controlled trials [18,20]. However, EASL suggests a 1–
2 year course of therapy with glitazones or vitamin E, preferably
associated with high-dose UDCA [17]; the AGA-AASLD-ACG
guideline advocates pioglitazone and vitamin E in non-diabetic
biopsy-proven NASH [21]; and the Chinese guideline proposes
liver protective and anti-inﬂammatory drugs, including Chinese
traditional and western medicines, in biopsy-proven NASH [19].
All guidelines agree that the underlying MRFs should be man-
aged as clinically required in NAFLD patients and drugs (particu-
larly statins for dyslipidemia) given as needed [17–21]. Bariatric
surgery, if otherwise indicated, is considered a valid option for
obese patients with NAFLD/NASH by all but one guideline [20].
Comments
The management of NAFLD patients is based on treatment of liver
disease alongside the associated MRFs [107,108]. Data on this
topic are many and perhaps confusing. Guidelines are inﬂuenced
by the year of publication. There are no medications speciﬁcally
approved for NASH, therefore drug treatments speciﬁcally aimed
at liver disease should be reserved to randomized trials with his-
tological end points. Interestingly, there is increasing evidence for
a beneﬁcial effect of pioglitazone and vitamin E on liver outcomes
in non-diabetic patients with biopsy-proven NASH [109], and a
recent cost-utility analysis indicated that, in subjects with NASH
and advanced ﬁbrosis, treatment with either pioglitazone or vita-
min E further to standard lifestyle changes is likely cost-effective
[110]. However, pioglitazone, vitamin E, and UDCA are not free of
side and toxic effects. Pioglitazone is associated with weight gain
and an increased risk of congestive heart failure, bone fractures,
and bladder cancer [111,112]. High-dose vitamin E has been
linked to increased all-cause mortality and an excess hemor-
rhagic stroke and prostate cancer [113,114]. High-dose UDCA
determines diarrhea and abdominal discomfort [115].
From a practical perspective, ameliorating cardiometabolic
risk proﬁle and histological disease activity, lifestyle-induced
weight loss should be recommended in all NAFLD patients, but
clear targets and suggestions on how to reach them are needed.
It should be highlighted that the common pharmacological treat-
ment of MRFs (particularly statins) is not contraindicated in
NAFLD [116].
As far as alcohol intake concerns, on the one hand, heavy con-
sumption is harmful to the liver [117] and should be discouraged.
On the other hand, light-moderate alcohol consumption might
well exert favorable effects on MRFs and, perhaps, on liver out-
comes [118–121]. However, in the absence of randomized con-
trolled trials, all guidelines discourage from prescribing low-
moderate alcohol consumption as preventive/therapeutic strat-
egy against NAFLD.How to follow-up NAFLD patients?
Analysis of reports from real-life clinical practice
Two-thirds and 22% of the surveyed Australian non-liver Special-
ists considered semi-annual LTs and 5 yearly LB as the most
effective method for monitoring NAFLD patients [11]. The major-
ity of French Hepatologists stated to monitor their NAFLD3 vol. 59 j 859–871 865
Table 3. How to manage NAFLD patients?
AGA, AASLD, ACG 
[21]
CLDA 
[19]
IASL 
[20]
EASL 
[17]
APWP 
[18]
Weight loss +
(3-5% to improve 
steatosis, 10% to 
improve NASH)
+
(more than 5%)
+
(0.5 Kg/wk)
+
(7%)
+
Hypocaloric diet + +
(500-1000 Kcal)
+ + +
Alcohol -,? - -
(particularly in obese 
NAFLD)
? /
Physical exercise + +
(4 times per week, 
150 min of aerobic 
exercise)
+ +
(150 min/wk 
moderate and 75 
min/wk vigorous 
exercise)
+
Educational therapy / + + + /
Metformin - -
(not contraindicated 
in diabetic NAFLD)
-
(not contraindicated 
in diabetic NAFLD)
- 
(not contraindicated 
in diabetic NAFLD)
-
(not contraindicated 
in diabetic NAFLD)
Glitazones +
(pioglitazone in 
non-diabetic biopsy-
proven NASH)
-
(not contraindicated 
in diabetic NAFLD)
-
(not contraindicated 
in diabetic NAFLD)
+
(NASH)
-
(not contraindicated 
in diabetic NAFLD)
Vitamin E +
(in non-diabetic 
biopsy-proven 
NASH)
+ - +
(NASH)
-
UDCA - + - +
(NASH)
-
Omega-3 FA -
(not 
contraindicated in 
hypertriglyceridemic 
NAFLD)
+ -
(not 
contraindicated in 
hypertriglyceridemic 
NAFLD)
-
(not 
contraindicated in 
hypertriglyceridemic 
NAFLD)
-
(not 
contraindicated in 
hypertriglyceridemic 
NAFLD) 
Statins -
(not contraindicated 
in dyslipidemic 
NAFLD)
-
(not contraindicated 
in dyslipidemic 
NAFLD)
-
(not contraindicated 
in dyslipidemic 
NAFLD)
-
(not contraindicated 
in dyslipidemic 
NAFLD)
-
(not contraindicated 
in dyslipidemic 
NAFLD)
Bariatric surgery -
(not contraindicated 
in eligible obese 
NAFLD)
+
(in obese patients 
refractory to medical 
measures)
-
(reserved to 
controlled studies)
+
(in morbidly obese 
NASH)
advanced fibrotic
+
(in obese patients 
refractory to medical 
measures)
+, recommended; , not recommended; /, not mentioned.
Reviewpatients with a mean number of two annual visits. LTs and US
were the most frequently performed procedures. 57% did not per-
form follow-up LB. With regards to MRFs, the majority of sur-
veyed specialists monitored glycemic and lipid proﬁle, and half
of those who assessed these parameters did so twice a year. How-
ever, surrogate markers of IR were never monitored by at least
50% [12].
Analysis of guidelines
There is universal consensus on the opportunity to perform
hepatological and cardiovascular follow-up in NAFLD patients
[17–21]. In NAFLD patients, semi-annual to annual hepatic mon-
itoring (non-invasive follow-up of ﬁbrosis, liver US, transami-866 Journal of Hepatology 201nases and LTs, markers of IR) is warranted [17,19]. Routine
repetition of LB is not indicated [21]. LB may be repeated not
earlier than 5 years after baseline LB in those patients in whom
ﬁbrosis progression is suspected [17]. Surveillance for eso-
phago-gastric varices [17,19,21] and HCC [17,19–21] in patients
with NASH-cirrhosis is advocated by the majority of societies.
All societies agree that a thorough assessment of MRFs and a
risk stratiﬁcation for CVD should be done in all NAFLD patients
[17–21]. These evaluations should be repeated every 6 months–
1 or 2 years [17,19,20]; the interval between check-ups should
be modulated on an individual basis, mirroring the severity of
liver disease and clustering of MRFs [17,20]. Generalized cancer
screening programs cannot be proposed to all NAFLD patients
[20]. Three out of ﬁve guidelines support the practice of oncologic3 vol. 59 j 859–871
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follow-up on individual basis [18–20]. Four scientiﬁc societies
speciﬁcally mention HCC among the cancer types to which
NAFLD patients may be prone [17,19–21]. The guideline of the
Asia-Paciﬁc region suggests to extend screening to those ‘‘cancers
whose incidence is increased by MS’’ [18].Comments
Considering the natural history of NAFLD, in terms of liver-
related, metabolic, cardiovascular and neoplastic complications,
patients affected warrant screening for MRFs and progressive
liver disease [5]. However, most of our understanding of the
natural course of hepatic and extrahepatic co-morbidities of
NAFLD is based on data from hepatological referral centers
evaluating selected groups of individuals [78]. Despite such
limitations, the increasing burden of NAFLD-related primary
liver cancers, principally HCCs [68,69] that may occur in non-
cirrhotic NAFLD [122], suggests the opportunity of more liberal
surveillance programs in these patients. However, speciﬁc rec-
ommendations about screening for HCC in NAFLD patients are
lacking and there are no data on the cost-effectiveness of sur-
veillance programs in these patients. Moreover, an increased
risk of colorectal and other types of cancers has been described
in NAFLD patients [66,67]. Efforts should be made to identify
the cardiometabolic, hepatologic, and oncologic risks in the
individual patient and to develop personally tailored follow-
up schedules.
Key Points 4
More attention should be paid to medical education and 
emphasis be placed in integrated NAFLD management. 
Questions to be answered are: 
• The definition of NAFLD natural history in the general 
population rather than in cohorts selected in tertiary 
referral centers,
• The definition of unequivocal NAFLD screening 
policies, 
• The assessment of methods and thresholds to define 
subtle IR, 
• The validation of decisional algorithms for LB 
submission, 
• The identification of methods to obtain healthy lifestyle 
changes targets, 
• The definition of personally-tailored cardiometabolic, 
hepatologic, and oncologic surveillance strategies
Pediatric NAFLDAnalysis of reports from real-life clinical practice
A survey among American primary pediatric care providers
showed that, in obese children with NAFLD, clinicians detected
hepatomegaly in only 1.4% and requested LTs in 12.5% of encoun-
ters, thus increasing the likelihood of a delayed or omitted diag-
nosis [15]. An Australian survey described that only 9% of GPsJournal of Hepatology 201used BMI charts to correctly diagnose childhood obesity and only
30% assessed for fatty liver in overweight/obese children [14].
Another survey among general pediatricians and pediatric
endocrinologists and gastroenterologists at two American aca-
demic hospitals conﬁrmed the underdiagnosis of obesity and
the underscreening for MS and NAFLD in children [16].
Analysis of guidelines
Among adult NAFLD guidelines, only the American one deals with
speciﬁc aspects of pediatric NAFLD [21]; a single position paper is
speciﬁcally devoted to diagnosis of NAFLD in children and adoles-
cents [22]. The American guideline and ESPGHAN statement dis-
agree with regard to screening for NAFLD in overweight/obese
children. American societies suggest that a formal recommenda-
tion cannot be made [21], whereas ESPGHAN states that NAFLD
should be suspected in all overweight/obese children and adoles-
cents older than 3 years especially if familiarity for NAFLD is
present [22].
According to ESPGHAN, abdominal US and LTs should be the
ﬁrst diagnostic step in suspected NAFLD children, followed by
exclusion of other liver diseases [22]. The two guidelines agree
that very young or lean children with liver steatosis should be
tested for monogenic metabolic disorders as causes of fatty liver
[21,22].
Both documents suggest similar indications for LB: to rule out
other treatable diseases, in cases of clinically suspected advanced
liver disease, before pharmacological/surgical treatment, and as
part of a structured intervention protocol or clinical research trial
[21,22]. Only the American guideline discusses treatment of pedi-
atric NAFLD. According to AGA-AASLD-ACG, intensive lifestyle
modiﬁcation is recommended as the ﬁrst-line treatment in pedi-
atric NAFLD. Metformin should be avoided. Vitamin E offers his-
tological beneﬁts to children with NASH, but conﬁrmatory
studies are needed before its use can be recommended in clinical
practice [21].
Comments
The rising incidence of obesity is paralleled by the increasing rec-
ognition of NAFLD also in children and adolescents [123,124].
Due to its potential progressive nature also in childhood
[125,126], early diagnosis and treatment are important in all
age-groups [127]. Therefore, shared standards to be used by phy-
sicians caring pediatric NAFLD are needed. Non-invasive diagnos-
tic strategy represents a key issue in pediatric practice. However,
contrasting with adult medicine, relatively scarce data are avail-
able in pediatric patients [105,128].Discussion
Given that NAFLD epidemic poses a heavy health-related costs
burden [129], an effort is justiﬁed to improve our medical ability
in clinical practice. A successful management plan requires a
motivated public, competent primary care doctors and special-
ists, and the implementation of multidisciplinary collaborative
networks [130]. However, studies in ‘‘real-life’’ practice have
shown that: (1) awareness of NAFLD is low in the general popu-
lation [13]; (2) knowledge of NAFLD and its complications is not
properly diffused among GPs who thus may fail to approach some3 vol. 59 j 859–871 867
Table 4. Open questions and future studies.
Screening • Which screening/surveillance policies for NAFLD in individuals with a single MRF and incomplete features of the
MS (e.g. T2D/obesity/dyslipidemia/hypertension alone or variedly associated)?
• What about screening in “NAFLD families”?
• What about screening for NAFLD in the setting of liver transplantation and major hepatic surgery?
• New lowered aminotransferases ranges? 
Initial evaluation • Which is the appropriate standard anthropometric, biochemical and imaging protocol to be followed to detect
NAFLD in clinical practice?
•  of thresholdDefinition
Definition
 and duration of alcohol consumption
• How to measure IR? Which ranges?
• A role for genetics [131]?
• A role for gut microbiota [132-134]?
Non-invasive 
assessment 
• NASH and fatty liver: two different entities?
• Which diagnostic protocols/algorithms in clinical practice?
• A role for novel US scoring systems [83,84]? 
Liver biopsy • Which criteria to restrict the number of individuals to submit to LB through strict pre-biopsy testing?
• More liberal use in those undergoing surgery for related conditions: gallstones, T2D, obesity?
• Is LB mandatory in clinical trials (when are surrogate indices enough?)? 
Management • Diets: standard criteria vs. general suggestions?
• Entity and types of physical activity?
• Role of psychological support-web-based platforms?
• Alcohol intake: pros and cons?
• When are drugs indicated?
• Iron depletion: when, why and how [135,136]?
• Gut microbiota: a role for probiotics/antibiotics? 
Follow-up •  of NAFLD natural history in unselected populations
• Cost-effective analysis of personally tailored screening/surveillance programs for liver-related, cardiovascular
and oncologic complications 
Children • Non-invasive diagnostic strategy of NAFLD in pediatric age
• To extend recommendations for NAFLD in adults to children vs.  recommendationsspecific  for pediatric NAFLD?
Reviewaspects of diagnosis and management [8–10,14,15]; (3) special-
ists other than hepatologists may miss a high proportion of
high-risk NAFLD patients and under-appreciate the overlap
between NAFLD and other MRFs [11,12,16]; (4) a proportion of
hepatologists risk to under-diagnose NALFD due to over-reliance
on transaminases [12].
Taken collectively, some data [8–16] support that more atten-
tion should be paid to medical education and emphasis be placed
in integrated NAFLD management. Indeed, awareness of guide-
lines and teaching programs consistently improve speciﬁc com-
petence of practicing physicians [8,9]. Moreover, increased
consistency among guidelines issued by different medical socie-
ties might eventually result in improved care of NAFLD in clinical
practice [9].
Here we have raised awareness of existing guidelines for NAFLD
and provided practical suggestions on the chief controversial topics
regarding diagnosis and management of NAFLD in daily practice.
In summary:
(1) A new positive deﬁnition of NAFLD, in which IR and MRFs
are the mainstay, is required. All guidelines agree that
patients suspected for NAFLD should undergo, as the initial
evaluation, a careful assessment of MRFs, competing
causes of liver steatosis (particularly HCV infection, alcohol
abuse and other), and co-existent CLD [17–21].
(2) Screening for NAFLD is not recommended in the general
population. All but one guideline [21] recommend screen-
ing for liver steatosis in patients with MRFs. Features of IR
should be considered a major prompt to detect NAFLD. US868 Journal of Hepatology 201should be the ﬁrst-line screening procedure for NAFLD
[79,80], whereas transaminases are not a useful tool in
clinical practice [85,86].
(3) Non-invasive tests are needed to predict NASH and ﬁbrosis
in NAFLD patients in order to restrict LB to selected indi-
viduals. NAFLD ﬁbrosis score and FibroScan could be useful
to this end [5,105]. LB is universally considered the diag-
nostic and prognostic standard in NAFLD. However, given
its invasiveness and costs, there is full agreement in limit-
ing its use on a case-by-case basis.
(4) All guidelines agree that lifestyle modiﬁcations are the
ﬁrst-line approach to manage NAFLD patients [17–21].
Bariatric surgery could be a valid option in morbidly obese
NAFLD patients non-responders to lifestyle changes. Phar-
macologic therapy should be restricted to clinical trials.
Speciﬁc drug treatments of MRFs (particularly statins)
are not contra-indicated in NAFLD patients.
(5) NAFLD patients should undergo regular follow-up not only
for liver-related complications but also for metabolic and
cardiovascular diseases. Oncologic screening/surveillance
should be considered on individual risk.
(6) Pediatric NAFLD shares the same MRFs as NAFLD in adults.
Diagnosis of NAFLD in children requires a thorough work-
up and exclusion of age-speciﬁc diagnoses.
In conclusion, current guidelines appear to be somewhat het-
erogeneous, if not contradictory, and fragmentary, suggesting the
opportunity to implement global recommendations concerning
the conduct to be followed in real-life clinical practice and much3 vol. 59 j 859–871
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research remains to be done about NAFLD screening, diagnosis,
management, and follow-up (Table 4).Financial support
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